Hereditary haemochromatosis (HH) is a genetic disorder in which abnormal iron handling leads to excessive iron accumulation in systemic tissues. Magnetic resonance imaging studies suggest excess iron ...

Background: Therapeutic outcome of Wilson’s disease (WD) significantly depends upon its early recognition. However, because of its rarity in community and protean manifestations, the diagnosis and ...

OBJECTIVE Neuropsychiatric symptoms are common in Huntington's disease and have been considered its presenting manifestation. Research characterising these symptoms in Huntington's disease is variable ...

Objective To perform a systematic review of cases reported in the literature in which a peripheral trauma preceded the onset of a movement disorder (MD). Methods Two reviewers independently searched ...

Background GBA variants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS ...

Background and objective: Cryoglobulinaemic neuropathy (CN) is probably common, as it is usually related to HCV infection. The aim of this study was to delineate the clinical spectrum of CN in a large ...

The clinical effects of botulinum toxin have been recognised since the end of the 19th century. It is the most potent neurotoxin known and it is produced by the gram negative anaerobic bacterium ...

Myalgia or muscle weakness is frequently observed during HIV infection (1), and 15% of HIV patients may have an increased serum creatine kinase (CK) level.1 Case reports or case series have suggested ...

Conclusion Autoimmune encephalitis-associated antibodies are a common request at the NHNN Neuroimmunology laboratory. The cost of tests over the last 5 years has been nearly £100000 to identify 10 ...

Objectives Guillain-Barré syndrome (GBS) is an acute clinical syndrome that is classically featured by rapidly evolving motor weakness, mild sensory loss and hypo- or areflexia. Uncommon variants such ...

RG6102 is a bispecific 2+1 monoclonal antibody (mAb) under development for the treatment of Alz- heimer’s disease (AD). It combines the anti-amyloid beta antibody gantenerumab with a transferrin ...

Objective Little is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the association between DMTs and infection-related ...